Wendy Spettigue1,2,3, Mark L Norris1,3,4, Danijela Maras5, Nicole Obeid1,3, Stephen Feder1,3,4, Megan E Harrison1,3,4, Rebecca Gomez6, Maeghan Cy Fu7, Katherine Henderson8, Annick Buchholz3,9. 1. Regional Eating Disorders Program, Children's Hospital of Eastern Ontario, Ottawa, Ontario. 2. Department of Psychiatry, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario. 3. Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario. 4. Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ontario. 5. Department of Psychology, University of Ottawa, Ontario. 6. Department of Psychiatry, University of Ottawa, Ontario. 7. Faculty of Medicine, University of Ottawa, Ontario. 8. Department of Psychology, Carleton University, Ontario. 9. Centre for Health Active Living, Children's Hospital of Eastern Ontario, Ottawa, Ontario.
Abstract
OBJECTIVES: To evaluate the effectiveness and safety of adjunctive olanzapine treatment for low weight adolescents with anorexia nervosa (AN). METHODS: A non-randomized open-label trial was conducted between 2010 and 2014. Participants received standard treatment and were invited to take olanzapine at study enrollment. Participants could accept, continue, or discontinue olanzapine as treatment progressed. Weight and psychological outcomes were monitored. RESULTS: Of 239 adolescents assessed, 65 met inclusion criteria, 38 enrolled in the study, and 32 were retained for analysis. Twenty-two participants took olanzapine (medication group) and ten participants did not (comparison group). Participants in the medication group demonstrated a higher rate of weight gain compared to those who did not receive olanzapine (p = .012). No serious adverse events were noted, although seven participants (31.8%) discontinued olanzapine due to a side effect. CONCLUSION: Preliminary results suggest that olanzapine may help facilitate weight gain in adolescents with AN. The importance of medical monitoring over the course of treatment is discussed. Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents; http://clinicaltrials.gov; NCT01184443.
OBJECTIVES: To evaluate the effectiveness and safety of adjunctive olanzapine treatment for low weight adolescents with anorexia nervosa (AN). METHODS: A non-randomized open-label trial was conducted between 2010 and 2014. Participants received standard treatment and were invited to take olanzapine at study enrollment. Participants could accept, continue, or discontinue olanzapine as treatment progressed. Weight and psychological outcomes were monitored. RESULTS: Of 239 adolescents assessed, 65 met inclusion criteria, 38 enrolled in the study, and 32 were retained for analysis. Twenty-two participants took olanzapine (medication group) and ten participants did not (comparison group). Participants in the medication group demonstrated a higher rate of weight gain compared to those who did not receive olanzapine (p = .012). No serious adverse events were noted, although seven participants (31.8%) discontinued olanzapine due to a side effect. CONCLUSION: Preliminary results suggest that olanzapine may help facilitate weight gain in adolescents with AN. The importance of medical monitoring over the course of treatment is discussed. Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents; http://clinicaltrials.gov; NCT01184443.
Authors: Amanda Malina; Jill Gaskill; Claire McConaha; Guido K Frank; Maria LaVia; Lisa Scholar; Walter H Kaye Journal: Int J Eat Disord Date: 2003-03 Impact factor: 4.861